DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Part of paid clinical trials in New York, New York.

Sponsor
Dizal Pharmaceuticals
Study ID
NCT05824585
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Lymphoma, Non-Hodgkin

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • DZD8586 — DRUG
    DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.

Study Details

This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.

Key Dates

Start date
May 15, 2023
Status verified
Aug 2025
Primary completion
Apr 30, 2027
Completion
Oct 30, 2027

Study Design

Enrollment
230 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: DZD8586

Primary Outcome Measure

Part A: Incidence of adverse events [ Time Frame: 30 days after the last dose, assessed up to 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Research siteNew YorkNew York10065-

Find similar trials in New York, NY

By research site
Research site· New York, NY

Related Studies